Functional characterization of two novel CYP2C19 variants (CYP2C19*18 and CYP2C19*19) found in a Japanese population

N. Hanioka, Y. Tsuneto, Y. Saito, T. Sumada, K. Maekawa, K. Saito, J. Sawada, S. Narimatsu

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Cytochrome P450 2C19 (CYP2C19) plays an important role in the metabolism of a wide range of therapeutic drugs and exhibits genetic polymorphism with interindividual differences in metabolic activity. We have previously described two CYP2C19 allelic variants, namely CYP2C19*18 and CYP2C19*19 with Arg329His/Ile331Val and Ser51Gly/Ile331Val substitutions, respectively. In order to investigate precisely the effect of amino acid substitutions on CYP2C19 function, CYP2C19 proteins of the wild-type (CYP2C19.1B having Ile331Val) and variants (CYP2C19.18 and CYP2C19.19) were heterologously expressed in yeast cells, and their S-mephenytoin 4'-hydroxylation activities were determined. The Km value of CYP2C19.19 for S-mephenytoin 4'-hydroxylation was significantly higher (3.0-fold) than that of CYP2C19.1B. Although no significant differences in Vmax values on the basis of microsomal and functional CYP protein levels were observed between CYP2C19.1B and CYP2C19.19, the Vmax/Km values of CYP2C19.19 were significantly reduced to 29-47% of CYP2C19.1B. By contrast, the Km, Vmax or Vmax/Km values of CYP2C19.18 were similar to those of CYP2C19.1B. These results suggest that Ser51Gly substitution in CYP2C19.19 decreases the affinity toward S-mephenytoin of CYP2C19 enzyme, and imply that the genetic polymorphism of CYP2C19*19 also causes variations in the clinical response to drugs metabolized by CYP2C19.

Original languageEnglish
Pages (from-to)342-355
Number of pages14
JournalXenobiotica
Volume37
Issue number4
DOIs
Publication statusPublished - Apr 2007

Fingerprint

Aromatase
Cytochrome P-450 Enzyme System
Mephenytoin
Population
Hydroxylation
Genetic Polymorphisms
Substitution reactions
Polymorphism
Amino Acid Substitution
Pharmaceutical Preparations
Metabolism
Yeast
Proteins
Yeasts
Cells
Amino Acids

Keywords

  • CYP2C19
  • CYP2C19*18
  • CYP2C19*19
  • Genetic polymorphism
  • S-mephenytoin 4'-hydroxylation

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Pharmacology
  • Toxicology
  • Health, Toxicology and Mutagenesis

Cite this

Hanioka, N., Tsuneto, Y., Saito, Y., Sumada, T., Maekawa, K., Saito, K., ... Narimatsu, S. (2007). Functional characterization of two novel CYP2C19 variants (CYP2C19*18 and CYP2C19*19) found in a Japanese population. Xenobiotica, 37(4), 342-355. https://doi.org/10.1080/00498250601127038

Functional characterization of two novel CYP2C19 variants (CYP2C19*18 and CYP2C19*19) found in a Japanese population. / Hanioka, N.; Tsuneto, Y.; Saito, Y.; Sumada, T.; Maekawa, K.; Saito, K.; Sawada, J.; Narimatsu, S.

In: Xenobiotica, Vol. 37, No. 4, 04.2007, p. 342-355.

Research output: Contribution to journalArticle

Hanioka, N, Tsuneto, Y, Saito, Y, Sumada, T, Maekawa, K, Saito, K, Sawada, J & Narimatsu, S 2007, 'Functional characterization of two novel CYP2C19 variants (CYP2C19*18 and CYP2C19*19) found in a Japanese population', Xenobiotica, vol. 37, no. 4, pp. 342-355. https://doi.org/10.1080/00498250601127038
Hanioka, N. ; Tsuneto, Y. ; Saito, Y. ; Sumada, T. ; Maekawa, K. ; Saito, K. ; Sawada, J. ; Narimatsu, S. / Functional characterization of two novel CYP2C19 variants (CYP2C19*18 and CYP2C19*19) found in a Japanese population. In: Xenobiotica. 2007 ; Vol. 37, No. 4. pp. 342-355.
@article{00c301e959dc496db1ff664aa650e6c4,
title = "Functional characterization of two novel CYP2C19 variants (CYP2C19*18 and CYP2C19*19) found in a Japanese population",
abstract = "Cytochrome P450 2C19 (CYP2C19) plays an important role in the metabolism of a wide range of therapeutic drugs and exhibits genetic polymorphism with interindividual differences in metabolic activity. We have previously described two CYP2C19 allelic variants, namely CYP2C19*18 and CYP2C19*19 with Arg329His/Ile331Val and Ser51Gly/Ile331Val substitutions, respectively. In order to investigate precisely the effect of amino acid substitutions on CYP2C19 function, CYP2C19 proteins of the wild-type (CYP2C19.1B having Ile331Val) and variants (CYP2C19.18 and CYP2C19.19) were heterologously expressed in yeast cells, and their S-mephenytoin 4'-hydroxylation activities were determined. The Km value of CYP2C19.19 for S-mephenytoin 4'-hydroxylation was significantly higher (3.0-fold) than that of CYP2C19.1B. Although no significant differences in Vmax values on the basis of microsomal and functional CYP protein levels were observed between CYP2C19.1B and CYP2C19.19, the Vmax/Km values of CYP2C19.19 were significantly reduced to 29-47{\%} of CYP2C19.1B. By contrast, the Km, Vmax or Vmax/Km values of CYP2C19.18 were similar to those of CYP2C19.1B. These results suggest that Ser51Gly substitution in CYP2C19.19 decreases the affinity toward S-mephenytoin of CYP2C19 enzyme, and imply that the genetic polymorphism of CYP2C19*19 also causes variations in the clinical response to drugs metabolized by CYP2C19.",
keywords = "CYP2C19, CYP2C19*18, CYP2C19*19, Genetic polymorphism, S-mephenytoin 4'-hydroxylation",
author = "N. Hanioka and Y. Tsuneto and Y. Saito and T. Sumada and K. Maekawa and K. Saito and J. Sawada and S. Narimatsu",
year = "2007",
month = "4",
doi = "10.1080/00498250601127038",
language = "English",
volume = "37",
pages = "342--355",
journal = "Xenobiotica",
issn = "0049-8254",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Functional characterization of two novel CYP2C19 variants (CYP2C19*18 and CYP2C19*19) found in a Japanese population

AU - Hanioka, N.

AU - Tsuneto, Y.

AU - Saito, Y.

AU - Sumada, T.

AU - Maekawa, K.

AU - Saito, K.

AU - Sawada, J.

AU - Narimatsu, S.

PY - 2007/4

Y1 - 2007/4

N2 - Cytochrome P450 2C19 (CYP2C19) plays an important role in the metabolism of a wide range of therapeutic drugs and exhibits genetic polymorphism with interindividual differences in metabolic activity. We have previously described two CYP2C19 allelic variants, namely CYP2C19*18 and CYP2C19*19 with Arg329His/Ile331Val and Ser51Gly/Ile331Val substitutions, respectively. In order to investigate precisely the effect of amino acid substitutions on CYP2C19 function, CYP2C19 proteins of the wild-type (CYP2C19.1B having Ile331Val) and variants (CYP2C19.18 and CYP2C19.19) were heterologously expressed in yeast cells, and their S-mephenytoin 4'-hydroxylation activities were determined. The Km value of CYP2C19.19 for S-mephenytoin 4'-hydroxylation was significantly higher (3.0-fold) than that of CYP2C19.1B. Although no significant differences in Vmax values on the basis of microsomal and functional CYP protein levels were observed between CYP2C19.1B and CYP2C19.19, the Vmax/Km values of CYP2C19.19 were significantly reduced to 29-47% of CYP2C19.1B. By contrast, the Km, Vmax or Vmax/Km values of CYP2C19.18 were similar to those of CYP2C19.1B. These results suggest that Ser51Gly substitution in CYP2C19.19 decreases the affinity toward S-mephenytoin of CYP2C19 enzyme, and imply that the genetic polymorphism of CYP2C19*19 also causes variations in the clinical response to drugs metabolized by CYP2C19.

AB - Cytochrome P450 2C19 (CYP2C19) plays an important role in the metabolism of a wide range of therapeutic drugs and exhibits genetic polymorphism with interindividual differences in metabolic activity. We have previously described two CYP2C19 allelic variants, namely CYP2C19*18 and CYP2C19*19 with Arg329His/Ile331Val and Ser51Gly/Ile331Val substitutions, respectively. In order to investigate precisely the effect of amino acid substitutions on CYP2C19 function, CYP2C19 proteins of the wild-type (CYP2C19.1B having Ile331Val) and variants (CYP2C19.18 and CYP2C19.19) were heterologously expressed in yeast cells, and their S-mephenytoin 4'-hydroxylation activities were determined. The Km value of CYP2C19.19 for S-mephenytoin 4'-hydroxylation was significantly higher (3.0-fold) than that of CYP2C19.1B. Although no significant differences in Vmax values on the basis of microsomal and functional CYP protein levels were observed between CYP2C19.1B and CYP2C19.19, the Vmax/Km values of CYP2C19.19 were significantly reduced to 29-47% of CYP2C19.1B. By contrast, the Km, Vmax or Vmax/Km values of CYP2C19.18 were similar to those of CYP2C19.1B. These results suggest that Ser51Gly substitution in CYP2C19.19 decreases the affinity toward S-mephenytoin of CYP2C19 enzyme, and imply that the genetic polymorphism of CYP2C19*19 also causes variations in the clinical response to drugs metabolized by CYP2C19.

KW - CYP2C19

KW - CYP2C1918

KW - CYP2C1919

KW - Genetic polymorphism

KW - S-mephenytoin 4'-hydroxylation

UR - http://www.scopus.com/inward/record.url?scp=34147150215&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34147150215&partnerID=8YFLogxK

U2 - 10.1080/00498250601127038

DO - 10.1080/00498250601127038

M3 - Article

C2 - 17455109

AN - SCOPUS:34147150215

VL - 37

SP - 342

EP - 355

JO - Xenobiotica

JF - Xenobiotica

SN - 0049-8254

IS - 4

ER -